MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
0.7003
+0.0525
+8.10%
Pre Market: 0.6839 -0.0164 -2.34% 08:47 12/05 EST
OPEN
0.6200
PREV CLOSE
0.6478
HIGH
0.7169
LOW
0.6200
VOLUME
4.94K
TURNOVER
0
52 WEEK HIGH
5.64
52 WEEK LOW
0.1986
MARKET CAP
71.38M
P/E (TTM)
-0.2524
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ATRA last week (1127-1201)?
Weekly Report · 1d ago
Atara Biotherapeutics To Present New Tab-cel® Clinical Data During Oral Session At ESMO Immuno-Oncology Annual Congress 2023
Atara biotherapeutics announces positive new data for tabelecleucel in patients with epstein-barr virus-positive post-transplant lymphoproliferative disease involving the central nervous system. The results will be presented at the european society for medical oncology.
Benzinga · 5d ago
Weekly Report: what happened at ATRA last week (1120-1124)?
Weekly Report · 11/27 09:10
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
NASDAQ · 11/24 17:29
Atara Biotherape: Statement of acquisition of beneficial ownership by individuals
Press release · 11/21 16:06
Atara Biotherape: Statement of changes in beneficial ownership of securities
Press release · 11/21 02:03
Weekly Report: what happened at ATRA last week (1113-1117)?
Weekly Report · 11/20 09:10
Atara Biotherape: Prospectus [Rule 424(b)(3)]
Press release · 11/18 02:10
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through the incorporation of engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). Its pipeline products include Tab-cel, ATA188, ATA2271, ATA3271, and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is used for the treatment of multiple sclerosis.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.